Redeye provides an update on Scandinavian ChemoTech following the Q3 2025 report. Sales developed broadly as expected, supported by continued momentum in treatment kit volumes. Cost control remains strong, and the company is now approaching operational breakeven on its recurring base. We make only minor estimate changes, mainly fine-tuning the cost base, while keeping our topline view largely intact. Our fair value range is raised, driven primarily by a lower perceived risk profile as the company matures.
LÄS MER
